Results 151 to 160 of about 19,369 (169)

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

Lancet, The, 2022
David M Gershenson, Austin Miller, William E Brady   +2 more
exaly  

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine, 2023
Vivek Subbiah, Ulrik Lassen, J-Y Blay
exaly  

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Lancet Oncology, The, 2022
Alexander Stein, Martin J B Van Den Bent, Jacques De Greve   +2 more
exaly  

Trametinib

Reactions Weekly, 2016
  +4 more sources

Trametinib

Reactions Weekly, 2015
openaire   +2 more sources

Structural basis for the action of the drug trametinib at KSR-bound MEK

Nature, 2020
Zaigham M Khan, Arthur Chow, Jayasudhan Reddy Yerabolu   +2 more
exaly  

Trametinib

Reactions Weekly, 2022
openaire   +1 more source

Recent developments in the medical and surgical treatment of melanoma

Ca-A Cancer Journal for Clinicians, 2014
Jonathan S Zager
exaly  

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Lancet, The, 2015
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas   +2 more
exaly  

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Lancet Oncology, The, 2020
Reinhard Dummer, Mario Santinami, Victoria Atkinson   +2 more
exaly